Europe Cervical Cancer Test Market size was valued at USD 1,370.26 million in 2021 and is growing at a CAGR of 4.8% from 2022- 2028 owing to technological advancements in cervical cancer diagnostic equipment and procedures. Moreover, unsafe sex with HPV-positive patients, lifestyle changes such as smoking, and obesity are also anticipated to upsurge the revenue of Europe market over the forecast period. However, an increase in the prevalence of cervical cancer in Europe region expected to drive the Europe market. For instance, according to International Agency for Research on Cancer 2012, the incidence rate of cervical cancer is 13.4 per 100,000 people and mortality rate is 4.9 per 100,000 people. However, mortality is decreasing owing to increase in the technological advancements of disease diagnostics and launching of low-cost test such as Visual Inspection with Acetic acid (VIA) test. Moreover, acquisitions and mergers and diversification of business segments are the strategies followed by the market players to increase their revenue in Europe cervical cancer test market. For instance, in July 2011, Roche has acquired mtm laboratories AG for the expansion of Cervical Cancer Test Market in the Europe region. According to World Health Organization Europe, approximately 28,000 women die from cervical cancer every year in the Europe region. The prevalence rate is higher in Germany, France, and U.K. (according to cancer research UK 2014, about 3,224 new cervical cancer cases were diagnosed in the U.K.). Due to change in lifestyles such as smoking, unsafe sex, and high adoption of technologically advanced diagnostic tests are anticipated to fuel the Europe cervical cancer test market. Moreover, government initiations for creating awareness about the cervical cancer diagnostic tests and increase in R&D investment for the innovation of novel technologies also expected to propel the Europe cervical cancer test market over the forecast period.
In April 2017, Roche launched the Cobas HPV assay for use on Cobas 8800 and Cobas 6600 systems for the screening of cervical cancer in countries accepting CE mark approval
In September 2016, Oncognostics developed GynTect 2.0 test used in the early detection of cervical cancer which received CE IVD mark in the European market in 2015
In September 2014, Abbott launched Real-time high-risk HPV test in the Europe for the primary screening of cervical cancer